|
|||
2013-03-07 08:00:00 CET 2013-03-07 08:01:38 CET REGULATED INFORMATION Biotie Therapies - Annual Financial ReportBiotie's Annual Financial Report and Corporate Governance Statement 2012 publishedBIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 7 March 2013 at 9.00 a.m. Biotie's Annual Financial Report and Corporate Governance Statement 2012 published Biotie Therapies Corp.' s Annual financial report for the financial period ended 31 December 2012 as well as Corporate Governance Statement 2012 have been published. The documents are attached in pdf format in this release. Both documents are also available at Biotie's website www.biotie.com in English and Finnish language. Turku, 7 March 2013 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900 e-mail: virve.nurmi@biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com About Biotie Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence (addiction) and post-traumatic stress disorder), and inflammatory and fibrotic liver disease. The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential. Biotie's most advanced product, Selincro(TM) (nalmefene), licensed to Lundbeck A/S, has on 28 February 2013 received European marketing authorization for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high level of alcohol consumption. In addition, Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant which is transitioning into Phase 3 development, Biotie shares are listed on NASDAQ OMX Helsinki Ltd. [HUG#1683596] |
|||
|